{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:55:17Z","timestamp":1769604917645,"version":"3.49.0"},"publisher-location":"Chichester, UK","reference-count":46,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002277.pub3","type":"reference-entry","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T01:11:33Z","timestamp":1202260293000},"source":"Crossref","is-referenced-by-count":65,"title":["Intravenous immunoglobulin for myasthenia gravis"],"prefix":"10.1002","author":[{"given":"Philippe","family":"Gajdos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus V","family":"Toyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD002277.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD002277.pub3-BIB2|cit2","doi-asserted-by":"crossref","unstructured":"Gajdos P Tranchant C Clair B Bolgert F Eymard B Stojkovic T Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g\/kg versus 2g\/kg: a randomized double blind clinical trial Archives of Neurology 2005 1689 93","DOI":"10.1001\/archneur.62.11.1689"},{"issue":"12","key":"10.1002\/14651858.CD002277.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"Ronager","year":"2001","journal-title":"Artificial Organs"},{"key":"10.1002\/14651858.CD002277.pub3-BIB4|cit4","unstructured":"Schuchardt V Kohler W Hund E Scheglmann K Fleisher E Jung K A randomized controlled trial of high dose intravenous immunoglobulin versus methylprednisolone in myasthenia gravis. An interim analysis. 2002 Data on file"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle & Nerve"},{"issue":"11","key":"10.1002\/14651858.CD002277.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD002277.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinte.1986.00360190143020","article-title":"High dose intravenous immunoglobulin in the management of myasthenia gravis","volume":"146","author":"Arsura","year":"1986","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002277.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000441-198805000-00005","article-title":"Effect of repeated doses of intravenous immunoglobulin in myasthenia gravis","volume":"295","author":"Arsura","year":"1988","journal-title":"American Journal of the Medical Sciences"},{"issue":"2 Pt 2","key":"10.1002\/14651858.CD002277.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/0090-1229(89)90083-4","article-title":"Experience with intravenous immunoglobulin in myasthenia gravis","volume":"53","author":"Arsura","year":"1989","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"10","key":"10.1002\/14651858.CD002277.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"8924","key":"10.1002\/14651858.CD002277.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002277.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.20269","article-title":"Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins","volume":"31","author":"Buchwald","year":"2005","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0404.1991.tb04912.x","article-title":"Treatment of myasthenia gravis with high dose intravenous immunoglobulin","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurologica Scandinavica"},{"issue":"27","key":"10.1002\/14651858.CD002277.pub3-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002277.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle & Nerve"},{"issue":"21","key":"10.1002\/14651858.CD002277.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02335664","article-title":"High dose intravenous immunoglobulin in myasthenia gravis","volume":"14","author":"Evoli","year":"1993","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"8381","key":"10.1002\/14651858.CD002277.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD002277.pub3-BIB22|cit22","first-page":"939","article-title":"Long term effects of plasma exchange in myasthenia gravis. Results from a randomised study","volume":"12","author":"Gajdos","year":"1983","journal-title":"Presse M\u00e9dicale"},{"issue":"8373","key":"10.1002\/14651858.CD002277.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","article-title":"High dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002277.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1749-6632.1987.tb51387.x","article-title":"High dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange","volume":"505","author":"Gajdos","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD002277.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V82.5.1415.bloodjournal8251415","article-title":"Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high dose intravenous immunoglobulin","volume":"82","author":"Godeau","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clinical Neurophamacology"},{"key":"10.1002\/14651858.CD002277.pub3-BIB28|cit28","series-title":"Neurological disorders: course and treatment","first-page":"947","author":"Hohlfeld","year":"1996"},{"issue":"8232","key":"10.1002\/14651858.CD002277.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002277.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD002277.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archneur.1981.00510080040003","article-title":"Plasmapheresis in refractory generalized myasthenia gravis","volume":"38","author":"Kornfeld","year":"1981","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Annals of Neurology"},{"issue":"8114","key":"10.1002\/14651858.CD002277.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD002277.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1986.03380100107031","article-title":"The utility of therapeutic plasmapheresis for neurological disorders","volume":"256","author":"NIH Consensus","year":"1986","journal-title":"The Journal of the American Medical Association"},{"issue":"24","key":"10.1002\/14651858.CD002277.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1001\/jama.1990.03450240091046","article-title":"Intravenous immunoglobulin: prevention and treatment of disease","volume":"264","author":"NIH Consensus","year":"1990","journal-title":"The Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD002277.pub3-BIB37|cit37","first-page":"497","article-title":"Studies in myasthenia gravis: review of a twenty year experience in over 1200 patients","volume":"38","author":"Osserman","year":"1971","journal-title":"The Mount Sinai Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002277.pub3-BIB38|cit38","first-page":"413","article-title":"A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia","volume":"33","author":"Perez-Nellar","year":"2001","journal-title":"Revista de Neurologia"},{"issue":"8000","key":"10.1002\/14651858.CD002277.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"issue":"9047","key":"10.1002\/14651858.CD002277.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002277.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002277.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archneur.1984.04050180037013","article-title":"Chronic long interval plasma exchange in myasthenia gravis","volume":"41","author":"Rodnitzky","year":"1984","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002277.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD002277.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub3-BIB45|cit45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D","article-title":"The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders","volume":"20","author":"Mech\u00e9","year":"1997","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD002277.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002277.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002277.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:11:11Z","timestamp":1628543471000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002277.pub3"}},"subtitle":[],"editor":[{"given":"Philippe","family":"Gajdos","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002277.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD002277.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,1,23]]}}}